{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:55:43Z","timestamp":1789480543309,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jaad.2024.09.014","type":"journal-article","created":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T04:04:20Z","timestamp":1733025860000},"page":"S31-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"S","title":["Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow"],"prefix":"10.1016","volume":"91","author":[{"given":"Daniella","family":"Jaguan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Goldfarb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2024.09.014_bib1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa ? - 15 years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2024.09.014_bib2","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s13555-023-00956-6","article-title":"Emerging treatments and the clinical trial landscape for hidradenitis suppurativa part I: topical and systemic medical therapies","volume":"13","author":"Fragoso","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2024.09.014_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fddsv.2023.1314077","article-title":"Introduction to small molecule drug discovery and preclinical development","volume":"3","author":"Southey","year":"2023","journal-title":"Front Drug Discov"},{"issue":"4","key":"10.1016\/j.jaad.2024.09.014_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mco2.181","article-title":"Small molecule inhibitors targeting the cancers","volume":"3","author":"Liu","year":"2022","journal-title":"MedComm"},{"issue":"2","key":"10.1016\/j.jaad.2024.09.014_bib5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/bjd\/ljad345","article-title":"Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape","volume":"190","author":"Krueger","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2024.09.014_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaad.2024.09.014_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/PTT.S303634","article-title":"Phosphodiesterase-4 inhibition in psoriasis","volume":"11","author":"Milakovic","year":"2021","journal-title":"Psoriasis Targets Ther"},{"issue":"1","key":"10.1016\/j.jaad.2024.09.014_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2024.09.014_bib9","first-page":"170","article-title":"Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study","volume":"18","author":"Kerdel","year":"2019","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2024.09.014_bib10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jaad.2017.02.026","article-title":"Apremilast in the treatment of moderate to severe hidradenitis suppurativa: a case series of 9 patients","volume":"76","author":"Weber","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.014_bib11","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"10.1016\/j.jaad.2024.09.014_bib12","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Fadel","year":"2011","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2024.09.014_bib13","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-\u03b3 and interleukin-17 production by human CD4+ T cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jaad.2024.09.014_bib14","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J Clin Invest"},{"issue":"3 Supplemental","key":"10.1016\/j.jaad.2024.09.014_bib15","doi-asserted-by":"crossref","first-page":"AB42","DOI":"10.1016\/j.jaad.2023.07.172","article-title":"43799 efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2, randomized, placebo-controlled study","volume":"89","author":"Kimball","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.014_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.014_bib17","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","article-title":"Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study","volume":"90","author":"Kirby","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2024.09.014_bib18","author":"Brunk"},{"issue":"19","key":"10.1016\/j.jaad.2024.09.014_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139930","article-title":"Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis","volume":"5","author":"Gudjonsson","year":"2020","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.jaad.2024.09.014_bib20","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jaad.2024.09.014_bib21","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.jaad.2023.05.076","article-title":"A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa","volume":"89","author":"Jepsen","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2024.09.014_bib22","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1111\/jdv.13233","article-title":"Mammalian target of rapamycin, insulin resistance and hidradenitis suppurativa: a possible metabolic loop","volume":"30","author":"Monfrecola","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.014_bib23","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/j.jaad.2017.11.061","article-title":"Activated mTORC1 signaling: the common driving force of type 2 diabetes and hidradenitis suppurativa","volume":"78","author":"De Vita","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2024.09.014_bib24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jaad.2020.06.042","article-title":"Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa","volume":"83","author":"Bettuzzi","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2024.09.014_bib26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/dth.15743","article-title":"Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast","volume":"35","author":"Agud-Dios","year":"2022","journal-title":"Dermatol Ther"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224028603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962224028603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T02:10:52Z","timestamp":1733883052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962224028603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0190962224028603"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2024.09.014","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective small molecule inhibitors for hidradenitis suppurativa: Today and tomorrow","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2024.09.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}